Skip to main content
Insurance Considerations for Pharmacists and Professional Liability in Compounding
COVID-19 Testing and Therapeutics
Minor Chapters Major Impacts: What USP 51, 61 and 1207 Mean for Your Practice
More than Selling Compounds
Webinar Q&A
Rapid Sterility Testing Strategies for Compounded Sterile Preparations
Webinar Q&A
Stability Testing: Science and Compliance
Discover New Business Opportunities for Your Pharmacy
Webinar Q&A
Rapid Sterility Testing
Webinar Q&A
USP 800 Update – What is the current status and how do pharmacists proceed?
Webinar Q&A
Beyond Use Date Strategies for Compounded Sterile Preparations
USP General Chapters and Compounded Monograph Chapters: Best Practices and Regulatory Guidance
Webinar Q&A
Medical Marijuana (THC and CBD) Pharmacology, Regulation, and Pharmacy Considerations
The Practical Use of the USP as a Primary Reference Resource in Compounded Formulations
Stability Studies: The Architecture Behind Establishing a Beyond-Use-Date
Compounded Sterile Products: Extending Beyond Use Dating and Batch Release Testing for 503A and 503B Facilities
An Inside Look at USP <71>
USP <800> and Environmental Monitoring Requirements
Stability Indicating Methods
Extending Beyond Use Dating for Compounding Preparations
Microbiology Testing: USP Requirements for Sterile and Non-Sterile Preparations
